Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues.

Diabetes Mellitus/drug therapy/immunology; Drug Hypersensitivity/prevention & control; Humans; Hypoglycemic Agents/administration & dosage/immunology; Insulin/administration & dosage/immunology; Insulin Infusion Systems

Abstract :

[en] The purification of animal insulin preparations and the use of human recombinant insulin have markedly reduced the incidence but not completely suppressed the occurrence of insulin allergy manifestations. Advances in technologies concerning the mode of delivery of insulin, i.e. continuous subcutaneous insulin infusion (CSII), and the use of insulin analogues, resulting from the alteration in the amino acid sequence of the native insulin molecule, may influence the immunogenicity and antigenicity of native insulin. Instead of increasing allergy reactions, CSII has been reported to represent a successful alternative treatment in diabetic patients presenting local or generalized allergy to insulin or other components (zinc, protamine) of conventional treatment. Most recent reports concern CSII-treated patients using short-acting insulin analogues (essentially insulin lispro), although the precise role of these insulin analogues remains unclear as allergy to them has also been described. Finally, data on antigenicity and immunogenicity of long-acting insulin analogues (glargine, detemir), which may mimic the basal insulin delivery with CSII, remain scarce at present.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Radermecker, Régis ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Language :

English

Title :

Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues.

Publication date :

2007

Journal title :

Diabetes/Metabolism Research and Reviews

ISSN :

1520-7552

eISSN :

1520-7560

Publisher :

John Wiley & Sons, Inc, Chichester, United Kingdom

Volume :

Issue :

Pages :

348-55

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 16 June 2009

Statistics

Number of views

286 (7 by ULiège)

Number of downloads

1302 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002; 25: 593-598.
Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003; 26: 1079-1087.
Colquitt J, Toyle P, Waugh N. Are analogues insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med 2003; 20: 863-866.
Radermecker RP, Scheen AJ. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev 2004; 20: 178-188.
Hirsch IB. Insulin analogues. N Engl J Med 2005; 352: 174-183.
Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs 2005; 65: 325-340.
Lawrence RD. Local insulin reactions. Lancet 1925; 1: 1125-1126.
Vialettes B. L'allergie à l'insuline. Diabete Metab 1986; 12: 169-172.
Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993; 16(Suppl. 3): 155-165.
Paley RG, Tunbridge RE. Dermal reactions to insulin therapy. Diabetes 1952; 1: 22-27.
Arkins JA, Engoring NH, Lennon E. The incidence of skin reactivity to insulin in diabetic patients. J Allergy 1962; 33: 69-72.
Patterson R, Roberts M, Grammer LC. Insulin allergy; reevaluation after two decades. Ann Allergy 1990; 64: 459-462.
Grammer LC. Immunologic reaction to insulin and other proteins. Immunol Allergy Clin North Am 1998; 18: 809-816.
Richardson T, Kerr D. Skin-related complications of insulin therapy. Epidemiology and emerging management strategies. Am J Clin Dermatol 2003; 4: 661-667.
Sola-Gazagnes A, Pecquet C. Allergie à l'insuline en 2003. Journées de Diabéologie de l'Hôtel Dieu, Flammarion Médecine-Sciences: Paris, 2004; 161-179.
Ratner RE, Phillips TM, Steiner M. Persistent cutaneous insulin allergy resulting from high-molecular-weight insulin aggregates. Diabetes 1990; 39: 728-833.
Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 923-954.
Ottesen JL, Nilsson P, Jami J, et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgene mouse model. Diabetologia 1994; 37: 1178-1185.
JiXiong X, Jianying L, Yulan C, Huixian C. The human insulin analog aspart can induce insulin allergy. Diabetes Care 2004; 27: 2084-2085.
Radermecker RP, Scheen AJ. Treatment of allergy to insulin using continuous subcutaneous insulin infusion with short-acting insulin analogues. Infusystems International 2004; 3: 1-5.
Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
Doyle EA, Weinzimer SA, Steffen AT, et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004; 27: 1554-1558.
Kahn CR, Rosenthal AS. Immunologic reactions to insulin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome. Diabetes Care 1979; 2: 283-295.
Grammer L. Insulin allergy. Clin Rev Allergy 1986; 4: 189-200.
Messaad D, Outtas O, Demoly P. Hypersensibilité aux insulines. Presse Med 2004; 33: 631-638.
Bodtger U, Wittrup M. A rational clinical approach to suspected insulin allergy: status after five years and 22 cases. Diabet Med 2005; 22: 102-106.
De Shazo RD, Boehm TM, Kumar D, Galloway JA. Dermal hypersensitivity reactions to insulin: correlations of three patterns to their histopathology. J Allergy Clin Immunol 1982; 69: 229-237.
Silva MER, Mendes MJM, Ursich MJM, et al. Human insulin allergy-immediate and late type III reactions in a long-standing IDDM patient. Diabetes Res Clin Pract 1997; 36: 67-70.
Katahira M, Hara I, Nishizaki T. Insulin allergy decreased by Humulin S (Humulin R) and not by insulin aspart or Actrapid Penfill (Penfill R). Diabet Med 2005; 22: 1454-1459.
Lee A-Y, Chey W-Y, Choi J, Jeon J-S. Insulin-induced drug eruptions and reliability of skin tests. Acta Derm Venereol 2002; 82: 114-117.
Primeau M-N, Adkinson NF Jr, Hamilton RG. Natural rubber pharmaceutical vial closures release latex allergens that produce skin reactions. J Allergy Clin Immunol 2001; 107: 958-962.
Shojaei AR, Haas DA. Local anesthetic cartridges and latex allergy: a literature review. J Can Dent Assoc 2002; 68: 622-626.
Roest MA, Shaw S, Orton DI. Insulin-injection-site reactions associated with type 1 latex allergy. N Engl J Med 2003; 348: 265-266.
Lougheed W, Albisser AM, Martindale HM, Chow JC, Clement JR. Physical stability of insulin formulations. Diabetes 1983; 32: 424-432.
Chantelau E, Lange G, Gasthaus M, Boxberger M, Berger M. Interaction between plastic catheter tubings and regular insulin preparations used for continuous subcutaneous insulin-infusion therapy. Diabetes Care 1987; 10: 348-351.
Melberg SG, Havelund S, Villumsen J, Brange J. Insulin compatibility with polymer materials used in external pump infusion systems. Diabet Med 1988; 5: 243-247.
Radermecker RP, Piérard GE, Scheen AJ. Lipodystrophy Reactions to Insulin: Effects of Continuous Insulin Infusion and New Insulin Analogues. Am J Clin Dermatol (in press).
Grant W, de Shazo RD, Frentz J. Use of low-dose continuous corticosteroid infusion to facilitate insulin pump use in local insulin hypersensitivity. Diabetes Care 1986; 9: 318-319.
Gin H, Aubertin J. Generalized allergy due to zinc and protamine in insulin preparation treated with insulin pump. Diabetes Care 1987; 10: 789-790.
Valentini U, Cimino A, Rocca L, Pelizzari R, Rotondi A, Tosoni C. CSII in management of insulin allergy. Diabetes Care 1988; 11: 97-98.
Nagai T, Nagai Y, Tomizawa T, Mori M. Immediate-type human insulin allergy successfully treated by continuous subcutaneous insulin infusion. Intern Med 1997; 36: 575-578.
Fineberg NS, Fineberg SG, Anderson JH, Birkett MA, Gibson RG, Hufferd S. Immunologic effects of insulin lispro [(Lys (B28), Pro (B29) human insulin)] in IDDM and NIDDM patients previously treated with insulin. Diabetes 1996; 45: 1750-1754.
Fineberg SE, Huang J, Brunelle R, Gulliya KS, Anderson JH Jr. Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes. Diabetes Care 2003; 26: 89-96.
Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Rastam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002; 25: 876-882.
Kumar D. Lispro analog for treatment of generalized allergy to human insulin. Diabetes Care 1997; 20: 1357-1359.
Abraham MR, Al-Sharafi BA, Saavedra GA, Khardori R. Lispro in the treatment of insulin allergy. Diabetes Care 1999; 22: 1916-1917.
Lluch-Bernal M, Fernandez M, Herrera-Pombo JL, Sastre J. Insulin lispro, an alternative in insulin hypersensitivity. Allergy 1999; 54: 186-187.
Panczei P, Hosszufalusi N, Horvath MM, Horvath A. Advantage of insulin lispro in suspected insulin allergy. Allergy 2000; 55: 418-419.
Adachi A, Fukunaga A, Horikawa T. A case of human insulin allergy induced by short-acting and intermediate-acting insulin but not by long-acting insulin. Int J Dermatol 2004; 43: 597-599.
Airaghi L, Lorini M, Tedeschi A. The insulin analog aspart: a safe alternative in insulin allergy. Diabetes Care 2001; 24: 2000.
Yasuda H, Nagata M, Moriyama H, et al. Human insulin analog insulin aspart does not cause insulin allergy. Diabetes Care 2001; 24: 2008-2009.
Kara C, Kutlu AO, Evliyaoglu O, Bilgili H, Yildirim N. Successful treatment of insulin allergy in a 1-year-old infant with neonatal diabetes by lispro and glargine insulin. Diabetes Care 2005; 28: 983-984.
Hermoso F, Vazquez M, Chaves G, Reviriego J, Andion R. Generalized allergy to human insulin treated with insulin lispro (Abstract). Diabetologia 1997; 40(Suppl. 1): A349.
Barranco R, Herrero T, Tomero P, et al. Systemic allergic reaction by a human insulin analog. Allergy 2003; 58: 536.
Yokoyama H, Fukumoto S, Koyama H, Emoto M, Kitagawa Y, Nishizawa Y. Insulin allergy; desensitization with crystalline zinc-insulin and steroid tapering. Diabetes Res Clin Pract 2003; 61: 161-166.
Mizuhashi S, Nakamura K, Mori Y, Noda M, Nakanishi K. Insulin allergy and immunologic insulin resistance caused by interleukin-6 in a patient with lung cancer. Diabetes Care 2006; 29: 1711-1712.
Castera V, Dutour-Meyer A, Koeppel M, Petijean C, Darmon P. Systemic allergy to human insulin and its rapid and long acting analogs: successful treatment by continuous subcutaneous insulin lispro infusion. Diabetes Metab 2005; 31: 391-400.
Takata H, Kumon Y, Osaki F, et al. The human insulin analogue aspart is not the almighty solution for insulin allergy. Diabetes Care 2003; 26: 253-254.
Frigerio G, Aubry M, Gomez F, et al. Desensitization-resistant insulin allergy. Allergy 1997; 52: 238-239.
Moriyama H, Nagata M, Fujihira K, et al. Treatment with human analog (GlyA21, ArgB31, ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type 1 diabetes. Diabetes Care 2001; 24: 411-412.
Durand-Gonzalez KN, Guillausseau N, Pecquet G, Gayno JP. Glargine insulin is not an alternative in insulin allergy. Diabetes Care 2003; 26: 2216.
Vernassiére G, Tréchot P, Guerci B, Commun N, Schmutz JL, Barbaud A. Deux premiers cas de sensibilisation retardée aux insulines humaines recombinantes modifiées (Abstract). Ann Dermatol Venereol 2004; 13: P1.
Moyes V, Driver R, Groom A, Mirakian R, Chowdhury TA. Insulin allergy in a patient with Type 2 diabetes successfully treated with continuous subcutaneous insulin infusion. Diabet Med 2006; 23: 204-206.
Darmon P, Castera V, Koeppel M-C, Petitjean C, Dutour A. Type III allergy to insulin detemir. Diabetes Care 2005; 28: 2980.
Lougheed WD, Zinman B, Strack TR, et al. Stability of insulin Lispro in insulin infusion systems. Diabetes Care 1997; 20: 1061-1065.
Defelippis MR, Bell MA, Heyob JA, Storms SM. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. Diabetes Technol Ther 2006; 8: 358-368.
Eapen SS, Connor EL, Gern JE. Insulin desensitisation with insulin lispro and an insulin pump in a 5-year-old child. Ann Allergy Asthma Immunol 2000; 85: 395-397.
Pratt EJ, Miles P, Kerr D. Localized insulin allergy treated with continuous subcutaneous insulin. Diabet Med 2001; 18: 514-516.
Näf S, Esmatjes E, Recasens M, et al. Continuous subcutaneous insulin infusion to resolve an allergy to human insulin. Diabetes Care 2002; 25: 634-635.
Durand-Gonzalez KN, Guillausseau N, Anciaux ML, Hentschel V, Gayno JP. Allergy to insulin in a woman with gestational diabetes mellitus: transient efficiency of continuous subcutaneous insulin lispro infusion. Diabetes Metab 2003; 29: 432-434.
Sola-Gazagnes A, Pecquet C, Radermecker R, et al. Successful treatment of insulin allergy in a type 1 diabetic patient by means of constant subcutaneous pump infusion of insulin. Diabetes Care 2003; 26: 2961-2962.
Imiela A, Tavernier J-Y, Carotte-Lefebvre I, Deverny F, Delaporte E, Lamblin C. Allergie à l'insuline humaine recombinante: à propos de 3 cas avec manifestations immédiates généralisées. Rev Franc Allergol Immunol Clin 2003; 43: 165-169.
Matheu V, Perez E, Hernandez M, et al. Insulin allergy and resistance successfully treated by desensitisation with Aspart insulin. Clin Mol Allergy 2005; 3: 16, Doi:10.1186/1476-7961-3-16.